Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics Inc (NQ: AQST )

2.685 -0.045 (-1.65%)
Streaming Delayed Price Updated: 10:59 AM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Aquestive Therapeutics Inc

< Previous 1 2 3 4 Next >
The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Earnings Outlook For Aquestive Therapeutics
Aquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Aquestive's AQST-109 Receives Fast Track Tag For Allergic Reactions
The FDA has granted Fast Track Designation to Aquestive Therapeutics Inc's (NASDAQ: AQST) AQST-109 for allergic reactions. AQST-109 is an orally delivered epinephrine-based product candidate for the... 
Via Benzinga
Looking Into Aquestive Therapeutics's Return On Capital Employed
Benzinga Pro data, Aquestive Therapeutics (NASDAQ:AQST) reported Q4 sales of $11.08 million. Earnings fell to a loss of $28.95 million, resulting in a 98.87% decrease from last... 
Via Benzinga
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative... 
Via Benzinga
Earnings Scheduled For March 8, 2022
Companies Reporting Before The Bell • Babcock & Wilcox (NYSE:BW) is likely to report quarterly earnings at $0.10 per share on revenue of $196.62 million. •... 
Via Benzinga
A Preview Of Aquestive Therapeutics's Earnings
Aquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-03-08. Here's what investors need to know before the announcement.... 
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
Week In Review: Adagene Forms $2.5 Billion, Four-Drug Partnership With Sanofi
Adagene will apply its technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights for two Heidelberg Pharma ADC candidates in... 
Via Talk Markets
Aquestive Highlights Early Data From Allergy Treatment Candidate AQST-109 Study
Aquestive Therapeutics Inc (NASDAQ: AQST) announced positive topline results from Part 1 of the EPIPHAST study for its AQST-109 epinephrine oral film. Part 1... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Kaleido Biosciences (NASDAQ:KLDO) stock rose 14.6% to $1.73 during Friday's pre-market session. The market value of their outstanding shares is at $73.6... 
Via Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 58.26% to $1.82 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 28.4... 
Via Benzinga
55 Biggest Movers From Yesterday
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8... 
Via Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining... 
Via Benzinga
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) stock moved upwards by 75.98% to $4.47 during Tuesday's pre-market session. The company's market cap stands at $62.8... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! We're kicking off the day with a dive into some of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
26 Stocks Moving in Tuesday's Pre-Market Session
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) rose 102% to $5.13 in pre-market trading after the company reported pan-coronavirus monoclonal antibody cocktail that retains... 
Via Benzinga
See Why Aquestive Therapeutics Shares Are Down More Than 30%
The FDA has notified Aquestive Therapeutics Inc (NASDAQ: AQST) that the agency is still considering the regulatory issues related to the approvability of Libervant and... 
Via Benzinga
The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Aptinyx (NASDAQ:APTX) shares rose... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
Via Benzinga
Exposures Product Safety
Aquestive Therapeutics, Inc. (AQST) Q3 2021 Earnings Call Transcript
AQST earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Valneva (NASDAQ:VALN) stock moved upwards by 29.61% to $49.9 during Monday's regular session. Valneva's stock is trading at a volume of 143.0K shares as of... 
Via Benzinga
Looking into Aquestive Therapeutics's Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, Aquestive Therapeutics's (NASDAQ:AQST) reported sales totaled $15.35 million. Despite a 23.55% in earnings, the... 
Via Benzinga
88 Biggest Movers From Yesterday
Gainers BeyondSpring Inc. (NASDAQ: BYSI) shares climbed 176% to close at $26.58 on Wednesday in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers BeyondSpring (NASDAQ:BYSI) stock increased by 337.79% to $42.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.